July 2024
FDA Raises Concerns Over Potential Overtreatment with AstraZeneca’s Imfinzi for NSCLC
AstraZeneca, Imfinzi, NSCLC, FDA, Overtreatment, Adcomm, Perioperative Treatment, Immune Checkpoint Inhibitors, Neoadjuvant Chemotherapy, Adjuvant Monotherapy
EU Regulatory Panel Rejects Eisai and Biogen’s Leqembi for Alzheimer’s Treatment
Leqembi, Alzheimer’s disease, Eisai, Biogen, European Medicines Agency, regulatory panel, approval rejection, adverse effects
European Regulators Reject Eisai and Biogen’s Alzheimer’s Drug Leqembi
Eisai, Biogen, Leqembi, Alzheimer’s disease, European Medicines Agency, drug rejection
Sun Pharma Secures FDA Approval for Leqselvi, a JAK Inhibitor for Severe Alopecia Areata
Sun Pharma, Leqselvi, FDA Approval, Alopecia Areata, JAK Inhibitor, Pfizer, Lilly, Immunology, Dermatology
FDA Advisers Call for Revamp of Perioperative Lung Cancer Trials Due to Frustration with AstraZeneca’s Imfinzi Design
FDA, Imfinzi, AstraZeneca, perioperative lung cancer trials, revamp, design issues
Biopharma Layoff Tracker 2024: Anokion, GlycoMimetics, Relay and More Cut Staff
Biopharma, Layoffs, 2024, Anokion, GlycoMimetics, Relay, Restructuring, Job Cuts, Industry Trends
Fierce Biotech Layoff Tracker 2024: GlycoMimetics Cuts 80% of Company; Anokion Undergoes Cuts
Biotech Layoffs, GlycoMimetics, Anokion, Pharmaceutical Industry, Job Cuts, Cost Reduction
Docs Embrace Takeda’s Eohilia, Creating Competition for Sanofi, Regeneron’s Blockbuster Dupixent
Takeda, Eohilia, Dupixent, Sanofi, Regeneron, Chronic Inflammatory Disease, Eosinophilic Esophagitis
BeiGene CEO Eyes Biologics Deals for New US Innovation Center in New Jersey
BeiGene, biologics, innovation center, New Jersey, deals, CEO, John Oyler